Quality-adjusted life expectancies in patients with rheumatoid arthritis - Comparison of index scores from EQ-5D, 15D, and SF-6D

Value in Health

Volumn 15, Issue 2, 2012, Pages 334-339

  Sørensen, Jan ^a   Linde, Louise ^b   Østergaard, Mikkel ^c   Hetland, Merete Lund ^b,c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b DANBIO Registry   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

15D; EQ 5D; quality adjusted life expectancies; rheumatoid arthritis; SF 6D

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DENMARK; EXPECTANCY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHORT FORM 12;

ADULT; AGED; AMBULATORY CARE; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DENMARK; FEMALE; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES;

EID: 84858634670     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.09.010     Document Type: Article

References (49)

1. Sullivan DF. A single index of mortality and morbidity. HSMHA Health Rep 1971;86:347-54.
2. Kaplan RM, Alcaraz JE, Anderson JP, Weisman M. Quality-adjusted life years lost to arthritis: effects of gender, race, and social class. Arthritis Care Res 1996;9:473-82. (Pubitemid 27036044)
3. Kaplan RM, Anderson JP, Kaplan CM. Modelling quality-adjusted life expectancy loss resulting from tobacco use in the United States. Soc Ind Res 2007;81:51-64. (Pubitemid 46476963)
4. Lee-Lewandrowski E, Lewandrowski K. Perspectives on cost and outcomes for point-of-care testing. Clin Lab Med 2009;29:479-89.
5. Cutler DM. The lifetime costs and benefits of medical technology. J Health Econ 2007;26:1081-100. (Pubitemid 350166638)
6. Williams A. Economics of coronary artery bypass grafting. BMJ (Clin Res Ed) 1985;291:326-9. (Pubitemid 15045122)
7. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009;12(Suppl. 1):S5-9.
8. Johnson FR. Moving the QALY forward or just stuck in traffic? [editorial]. Value Health 2009;12(Suppl. 1):S38 -9.
9. Stein K, Fry A, Round A, et al. What value health? A review of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy 2005;4:219-28. (Pubitemid 43242210)
10. Tosh JC, Longworth LJ, George E. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health 2011;14:102-9.
11. Kind P. Size matters: EQ-5D in transition. Med Care 2007;45:809-11.
12. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17:13-35. (Pubitemid 30072853)
13. Terwee CB, Dekker FW, Wiersinga WM, et al. On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res 2003;12:349-62. (Pubitemid 36612040)
14. Linde L, Sorensen J, Ostergaard M, et al. Health-related quality of life: validity, reliability, and responsiveness of SF-36, EQ-15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008;35:1528 -37.
15. Linde L, Sorensen J, Ostergaard M, et al. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010;37:285-90.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
17. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
18. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23(5, Suppl. 39):S14-8. (Pubitemid 46657507)
19. Thorsen H, Hansen TM, McKenna SP, et al. Adaptation into Danish of the Stanford Health Assessment Questionnaire (HAQ) and the Rheumatoid Arthritis Quality of Life Scale (RAQoL). Scand J Rheumatol 2001;30:103-9. (Pubitemid 32250800)
20. Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic Publishers, 2003.
21. Gudex C, Sorensen J. EuroQol: et generisk mål for helbredstilstand. Månedsskrift for Praktisk Lægegerning 1998;76:1339-45.
22. Kind P. A five-level version of EQ-5D (contributed podium presentations). Value Health 2004;7:637-57.
23. JanssenMF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health 2008;11:275-84. (Pubitemid 351473607)
24. Janssen MF, Birnie E, Bonsel GJ. Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods. Qual Life Res 2008;17:463-73.
25. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Dordrecht: Springer, 2007.
26. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health 2009;37:459-66.
27. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001;33:328-36. (Pubitemid 32675373)
28. Wittrup-Jensen K. Measurement and Valuation of Health-Related Quality of Life. Denmark: Faculty of Social Sciences, University of Southern Denmark, 2002.
29. Ware J Jr., Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33. (Pubitemid 126433231)
30. Gandhi SK, Salmon JW, Zhao SZ, et al. Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. Clin Ther 2001;23:1080-98. (Pubitemid 32709629)
31. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851-9. (Pubitemid 39456916)
32. Brazier JE, Rowen D, Hanmer J. Revised SF-6D scoring programmes: a summary of improvements. PRO Newslett 2008;40:14-5.
33. Krinsky I, Robb AL. On approximating the statistical properties of elasticities. Rev Econ Stat 1986;68:715-20.
34. Hole AR. A comparison of approaches to estimating confidence intervals for willingness to pay measures. Health Econ 2007;16:827-40. (Pubitemid 47215133)
35. Hawthorne G, Richardson J, Day NA. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann Med 2001;33:358-70. (Pubitemid 32675377)
36. Harrison MJ, Davies LM, Bansback NJ, et al. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res 2009;18:1195-205.
37. Quercioli C, Messina G, Barbini E, et al. Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools: comparison of three questionnaire scores. Eur J Health Econ 2009;10:389-97.
38. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82. (Pubitemid 40126441)
39. Stavem K, Froland SS, Hellum KB. Comparison of preference-based utilities of the 15D, EQ-5D and SF-6D in patients with HIV/AIDS. Qual Life Res 2005;14:971-80. (Pubitemid 40685221)
40. KontodimopoulosN, Pappa E, Chadjiapostolou Z, et al. Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications. Eur J Health Econ 2010. Dec 5. [Epub ahead of print].
41. Lillegraven S, Kristiansen IS, Kvien TK. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:1762-7.
42. Kontodimopoulos N, Aletras VH, Paliouras D, Niakas D. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health 2009;12:1151-7.
43. Wittrup-Jensen K. Measurement and Valuation of Health-Related Quality of Life [thesis]. University of Southern Denmark, 2006.
44. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92. (Pubitemid 34143147)
45. Harrison MJ, Davies LM, Bansback NJ, et al. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res 2009;18:1195-205.
46. Linde L, Sorensen J, Ostergaard M, et al. Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? J Rheumatol 2010;37:285-90.
47. Linde L, Sorensen J, Ostergaard M, et al. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008;35:1528-37.
48. Sach TH, Barton GR, Jenkinson C, et al. Comparing cost-utility estimates: does the choice of EQ-5D or SF-6D matter? Med Care 2009;47:889-94.
49. Bronnum-Hansen H, Juel K, Davidsen M, Sorensen J. Impact of selected risk factors on quality-adjusted life expectancy in Denmark. Scand J Public Health 2007;35:510-5. (Pubitemid 47470884)